Literature DB >> 15885127

Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen.

Wei Li1.   

Abstract

Full scale B-cell activation requires not only B-cell receptor (BCR) engagement with antigen, but also costimulatory signals provided by T helper cells through the CD40-CD40 ligand (CD40L) interaction. It is hypothesized that a fusion protein of an antigen and soluble CD40L (CD40LT) would selectively target the costimulation to antigen-specific B cells, leading to synergy in the antibody response. This hypothesis was investigated by fusing green fluorescence protein (GFP), a generic antigen, with mouse CD40LT. Studies revealed that immunization in mice with the plasmid encoding GFP-CD40LT fusion protein led to synergistic induction of GFP-specific antibodies, while control plasmid(s) for GFP, CD40LT, or GFP plus CD40LT did not. Immunization with a single dose of the fusion protein also provoked a vigorous GFP-specific immunoglobulin G1 antibody response, but not other antibody isotypes. These results suggest that GFP-CD40LT fusion protein induces a GFP-specific B-cell activation and antibody response in an antigen-guided fashion. The potential application of this novel strategy in vaccine development is discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885127      PMCID: PMC1782153          DOI: 10.1111/j.1365-2567.2005.02141.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

Review 1.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).

Authors:  A E Morris; R L Remmele; R Klinke; B M Macduff; W C Fanslow; R J Armitage
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

Review 3.  CD40 and CD154 in cell-mediated immunity.

Authors:  I S Grewal; R A Flavell
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

Review 4.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  Differential induction of cytokine genes and activation of mitogen-activated protein kinase family by soluble CD40 ligand and TNF in a human follicular dendritic cell line.

Authors:  S M Park; H S Kim; J Choe; T H Lee
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

Review 6.  Immune regulation by CD40 and its ligand GP39.

Authors:  T M Foy; A Aruffo; J Bajorath; J E Buhlmann; R J Noelle
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

Review 7.  Functional dissection of BCR signaling pathways.

Authors:  T Kurosaki
Journal:  Curr Opin Immunol       Date:  2000-06       Impact factor: 7.486

8.  CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.

Authors:  S Gurunathan; K R Irvine; C Y Wu; J I Cohen; E Thomas; C Prussin; N P Restifo; R A Seder
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

Review 9.  Immunotoxins in cancer therapy.

Authors:  R J Kreitman
Journal:  Curr Opin Immunol       Date:  1999-10       Impact factor: 7.268

10.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  4 in total

1.  Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.

Authors:  Sheryl L Gares; Karl P Fischer; Stephen E Congly; Stacey Lacoste; William R Addison; D Lorne Tyrrell; Klaus S Gutfreund
Journal:  Clin Vaccine Immunol       Date:  2006-08

2.  Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate.

Authors:  Ileanet Ávalos; Thailin Lao; Elsa María Rodríguez; Yasser Zamora; Alianet Rodríguez; Ailyn Ramón; Gilda Lemos; Ania Cabrales; Monica Bequet-Romero; Dionne Casillas; Ivan Andújar; Luis Ariel Espinosa; Luis Javier González; Yanitza Alvarez; Yamila Carpio; Mario Pablo Estrada
Journal:  Vaccines (Basel)       Date:  2022-06-03

3.  A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.

Authors:  Mark Melchers; Katie Matthews; Robert P de Vries; Dirk Eggink; Thijs van Montfort; Ilja Bontjer; Carolien van de Sandt; Kathryn David; Ben Berkhout; John P Moore; Rogier W Sanders
Journal:  Retrovirology       Date:  2011-06-20       Impact factor: 4.602

4.  Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.

Authors:  Valentina Ceglia; Sandra Zurawski; Monica Montes; Mitchell Kroll; Aurélie Bouteau; Zhiqing Wang; Jerome Ellis; Botond Z Igyártó; Yves Lévy; Gerard Zurawski
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.